FOCUSED ON THE FUTURE OF
BLADDER
CANCER
Passionate about developing and delivering bladder-sparing immunotherapies
At CG Oncology, we envision a world where patients with bladder cancer live with dignity and an improved quality of life. Through our pioneering work and unwavering commitment, we are making a meaningful difference for patients and their loved ones—together.
Our Science
Cretostimogene
grenadenorepvec
Cretostimogene is an intravesically delivered oncolytic immunotherapy (OIT) with a dual mechanism of action. It has been evaluated in an extensive clinical development program, with data supporting its potential to treat multiple types of non-muscle invasive bladder cancer (NMIBC). Cretostimogene is an investigational drug and is not approved by any regulatory agency. Its safety and efficacy has not been established.
